Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

Abstract

This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent is associated with lower risk for Alzheimer's disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases which are mediated in part by TNF and for which a TNF blocker is an approved treatment. The analysis compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. Adjusted odds ratios (AORs) were estimated using the Cochran-Mantel-Haenszel (CMH) method and presented with 95% confidence intervals (CIs) and p-values. RA was associated with a higher risk for AD (Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02-2.10), Pvalue <0.0001) as did psoriasis (

COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States

“…Specifically, disease terms are coded using the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT), a global standard for health terms that provides the core general terminology for EHRs [19]. Previous studies showed that with this large-scale and standardized EHR database, large case-control studies can be undertaken efficiently [20][21][22][23][24], including our recent studies [23,24].…”

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers

“…Relatively recently, reports have appeared in the literature about the application of MTX in the treatment of neurological diseases MG [302] and AD (as a drug potentially able to reduce the risk of dementia) [103][104][105][106]. However, these medical experiments have been conducted on small population sizes and, up to now, without significant results, and more detailed studies are needed for determining the conclusive effect of MTX with regards to these diseases.…”

“…According to the other research papers, MTX is associated with a lower risk for AD. Based on this knowledge, therapy with MTX shows promise application as a potential treatment for AD [105,106].…”

Therapeutic Potential of TNF-α Inhibition for Alzheimer’s Disease Prevention

“…Systemic inflammatory diseases such as rheumatoid arthritis (RA), inflammatory bowel disease, and psoriasis, which in part are mediated by TNF ( Fig. 1), heighten risk for AD, and these diseases are also approved indications for TNF blocking agents [15]. If the increased risk of AD is in part due to TNF, then TNF blocking agents could be expected possibly decrease risk of AD.…”

“…1. Adjusted odds ratio (AOR) for a diagnosis code of dementia associated with a diagnosis for an inflammatory disease compared to the non-inflammatory group disease [15]. AS, ankylosing spondylitis; Crohn's, Crohn's disease; IBD, inflammatory bowel disease; PA, psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis.…”